Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Oishi, Masakatsu ^a   Iizumi, Yosuke ^a   Taniguchi, Tomoyuki ^a   Goi, Wakana ^a   Miki, Tsuneharu ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; APIGENIN; DEATH RECEPTOR 5; GENISTEIN; MESSENGER RNA; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RIBOSOME PROTEIN; RIBOSOME PROTEIN S9; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENINE NUCLEOTIDE TRANSLOCATOR 2; ANTINEOPLASTIC AGENTS; APIGENIN; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; GENISTEIN; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84874216375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055922     Document Type: Article

References (32)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-2513.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
4. Bracarda S, Logothetis C, Sternberg CN, Oudard S, (2011) Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int 107: 13-20.
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
6. Srivastava RK, (2001) TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia 3: 535-546.
7. Johnstone RW, Frew AJ, Smyth MJ, (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
8. Zhang L, Fang B, (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237.
9. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, et al. (2006) The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 5: 945-951.
10. Ding J, Polier G, Köhler R, Giaisi M, Krammer PH, et al. (2012) Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 Expression. J Biol Chem 287: 641-649.
11. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, et al. (2007) Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 67: 8274-8284.
12. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, et al. (2008) Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68: 8918-8927.
13. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, et al. (2005) Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24: 7180-7189.
14. Szliszka E, Czuba ZP, Jernas K, Król W, (2008) Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Mol Sci 9: 56-64.
15. Belzacq AS, Vieira HL, Kroemer G, Brenner C, (2002) The adenine nucleotide translocator in apoptosis. Biochimie 84: 167-176.
16. Chevrollier A, Loiseau D, Reynier P, Stepien G, (2011) Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism. Biochim Biophys Acta 1807: 562-567.
17. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, et al. (2006) Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 66: 9143-9152.
18. Jang JY, Choi Y, Jeon YK, Kim CW, (2008) Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 10: R11.
19. Jang JY, Jeon YK, Choi Y, Kim CW, (2010) Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression. Mol Cancer 9: 262.
20. Sharaf el dein O, Mayola E, Chopineau J, Brenner C, (2011) The adenine nucleotide translocase 2, a mitochondrial target for anticancer biotherapy. Curr Drug Targets 12: 894-901.
21. Hellebrand EE, Varbiro G, (2010) Development of mitochondrial permeability transition inhibitory agents: a novel drug target. Drug Discov Ther 4: 54-61.
22. Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, Handa H, (2009) Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem Rec 9: 66-85.
23. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, et al. (2010) Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
24. Jin CY, Park C, Cheong J, Choi BT, Lee TH, et al. (2007) Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 257: 56-64.
25. Chan LP, Chou TH, Ding HY, Chen PR, Chiang FY, et al. (2012) Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim Biophys Acta 1820: 1081-1091.
26. Tsaytler P, Harding HP, Ron D, Bertolotti A, (2011) Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 332: 91-94.
27. Urusova DV, Shim JH, Kim DJ, Jung SK, Zykova TA, et al. (2011) Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1. Cancer Prev Res 4: 1366-1377.
28. Xu Y, Xin Y, Diao Y, Lu C, Fu J, et al. (2011) Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS One 6: e29169.
29. Budhraja A, Gao N, Zhang Z, Son YO, Cheng S, et al. (2012) Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther 11: 132-142.
30. Torkin R, Lavoie JF, Kaplan DR, Yeger H, (2005) Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol Cancer Ther 4: 1-11.
31. Szliszka E, Krol W, (2011) The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J Cancer Prev 20: 63-69.
32. Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, et al. (2007) RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447: 864-868.